These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 24706659

  • 1. Oncology drug discovery: planning a turnaround.
    Toniatti C, Jones P, Graham H, Pagliara B, Draetta G.
    Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. How can attrition rates be reduced in cancer drug discovery?
    Moreno L, Pearson AD.
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [Abstract] [Full Text] [Related]

  • 4. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S, Marshall LV, Carceller Lechon F, Pearson AD, Moreno L.
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [Abstract] [Full Text] [Related]

  • 5. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA, Camp F, Miknyoczki S.
    Biochem Pharmacol; 2014 Jan 01; 87(1):150-61. PubMed ID: 23817077
    [Abstract] [Full Text] [Related]

  • 6. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, Bradley-Garelik MB, Saha V, Pearson A, Zwierzina H.
    Eur J Cancer; 2015 Jan 01; 51(2):218-24. PubMed ID: 25434924
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A, Massard C, Soria JC.
    Curr Opin Oncol; 2014 May 01; 26(3):340-6. PubMed ID: 24709975
    [Abstract] [Full Text] [Related]

  • 10. Progress towards personalized medicine.
    Bates S.
    Drug Discov Today; 2010 Feb 01; 15(3-4):115-20. PubMed ID: 19914397
    [Abstract] [Full Text] [Related]

  • 11. Development of anti-cancer drugs.
    Arrondeau J, Gan HK, Razak AR, Paoletti X, Le Tourneau C.
    Discov Med; 2010 Oct 01; 10(53):355-62. PubMed ID: 21034677
    [Abstract] [Full Text] [Related]

  • 12. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E, Masuda S, Kimura H.
    J Clin Pharm Ther; 2012 Oct 01; 37(5):547-52. PubMed ID: 22428857
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J, Emons G, Pinski J, Schally AV.
    Expert Opin Investig Drugs; 2012 Jun 01; 21(6):891-9. PubMed ID: 22577891
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [New systemic therapies in oncology].
    Zaman K, Ketterer N, Vulliémoz D, Stupp R, Leyvraz S.
    Rev Med Suisse; 2005 May 18; 1(20):1361-2, 1364-5. PubMed ID: 15991629
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [New therapeutic strategies in oncology].
    Bohuon C.
    Ann Pharm Fr; 2010 Jul 18; 68(4):203-4. PubMed ID: 20637352
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.